C2i Genomics Appoints Chief Medical Officer to Scale Its AI-Powered Cancer Detection Platform Globally

C2i Genomics, a cancer intelligence company, today announced the appointment of Glenn Pomerantz MD, JD as Chief Medical Officer (CMO), as well as two additional leadership hires across business development and data science. The leadership expansion comes on the heels of a recent $100 million financing round, uniquely positioning the company to advance the power of its cancer intelligence platform and accelerate commercialization globally. 

Glenn Pomerantz MD, JD brings over 30 years of healthcare experience to the C2i Genomics executive team. Dr. Pomerantz has successfully led and collaborated on strategic large-scale transformational initiatives across both the payor and clinical sectors. As an industry veteran, he will support the global scale and commercialization of the C2-Intelligence Platform, C2i’s AI-powered, cloud-based cancer detection technology. 

“C2i Genomics lives at the cutting edge of healthcare innovation: its data-driven platform offers insight into disease progression with far greater speed and accuracy, and its cloud-based technology can be deployed globally, at scale, to reach even more patient lives,” commented Pomerantz. “After three decades in the healthcare sector, I am privileged to join this renowned team and begin our work together to increase the accessibility of cancer treatment.”
 
In addition to Pomerantz, C2i Genomics welcomes Jonathan Rosenfeld, Ph.D. as Vice President of Data Science, and Casey Frankenberger, Ph.D., as Vice President of Business Development, Americas. 

As VP Data Science, Rosenfeld brings his passion for deep learning in engineering and over 15 years of technical leadership experience straddling diverse industries and cutting-edge research to C2i Genomics --- further advancing innovations to inform patient treatment via the C2-Intelligence Platform.

As VP Business Development, Frankenberger will establish and manage collaborations and strategic corporate partnerships utilizing C2i’s technology across the Americas. An accomplished scientist, leader and consultant, Frankenberger brings over two decades of experience across commercial, clinical and translational research in precision medicine.  His career includes the development of early technology at Tempus and most recently as the Chief Informatics Officer at Rush University Medical Center.

“C2i has experienced momentous growth this year in support of our mission to develop highly precise cancer detection methods, to inform more impactful treatment decisions,” said Asaf Zviran, co-founder and CEO of C2i Genomics. “As we continue to scale our intelligence platform, I’m honored to welcome these leaders to our team. Their collective experience in the medical field sets us up for continued innovation and assured success.”

The leadership expansion comes soon after C2i’s recent network expansion collaboration with Premier, Inc., and the initiation of its global commercial launch through its partnership with NovogeneAIT Genomics. These three new hires will bring decades of combined experience to the company to help build upon a proven legacy of globally acclaimed cancer treatment. 

For companies interested in deploying the C2-Intelligence Platform, please visit www.c2i-genomics.com. 

About C2i Genomics 
Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 2mL blood) whole-genome sequencing to provide up to 100x more sensitive detection than competing liquid biopsy companies. With a headquarters in NYC, CLIA lab in Cambridge, MA, and an R&D center in Israel, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated computation and AI, C2i enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. For more information, please visit www.c2i-genomics.com. 
 

Contact Information

Kathryn Ryan

PR for C2i Genomics

VSC for C2i Genomics

Contact via E-mail